Intragroup changes of selected outcome variables in the intention to treat analysis
| Sulfasalazine (n=17) | Placebo (n=16) | |||||
|---|---|---|---|---|---|---|
| Baseline | Final | p Value | Baseline | Final | p Value | |
| VAS, visual analogue scale. | ||||||
| *p=0.03; †p=0.04. | ||||||
| Active joints (count) | 3.9 (1.9) | 2.1 (2.8) | 0.01 | 5.3 (3.2) | 3.0 (4.2) | 0.04 |
| Tender entheses (count) | 7.3 (5.6) | 4.7 (5.6) | 0.007 | 9.3 (4.8) | 4.8 (5.7) | 0.004 |
| Areas of foot tenderness (count) | 8.3 (6.2) | 5.0 (6.6) | 0.007 | 9.0 (5.1) | 3.6 (5.4) | 0.02 |
| Areas of foot swelling (count) | 7.3 (4.8) | 4.1 (5.6) | 0.01 | 8.8 (5.2) | 4.7 (5.3) | 0.009 |
| Pain VAS (0–100 mm) | 59.2 (25.2) | 32.3 (26.5) | 0.000 | 56.2 (19.6) | 31.6 (23.4) | 0.01 |
| Morning stiffness (min) | 8.3 (14.6) | 6.5 (21.7) | 0.4 | 33.5 (36.0) | 9.1 (16.1) | 0.01 |
| Anterior spinal flexion (cm) | 5.5 (1.3) | 6.2 (1.4) | 0.03 | 5.4 (2.4) | 5.7 (2.6) | 0.1 |
| Lumbar pain (No (%) patients) | 5 (29) | 1 (6) | 0.18 | 8 (50) | 3 (19) | 0.137 |
| Cervical pain (No (%) patients) | 3 (18) | 0 | 0.22 | 4 (25) | 3 (19) | 0.99 |
| Physician efficacy assessment (No (%) patients)* | ||||||
| Improved | 10 (59) | 4 (25) | ||||
| Unchanged | 3 (18) | 10 (63) | ||||
| Worsened | 4 (24) | 2 (13) | ||||
| Patient efficacy assessment (No (%) patients)† | ||||||
| Improved | 11 (65) | 4 (25) | ||||
| Unchanged | 2 (12) | 7 (44) | ||||
| Worsened | 4 (24) | 5 (31) | ||||